Israel’s Pluristem Therapeutics (reported here previously) has been approved by German’s health regulatory authority to conduct a Phase 2 clinical trial of its PLX PAD stem cells on 40 serious Covid-19 patients. Pluristem is already conducting a 140-patient Phase 2 … Continue reading →

Seven of the eight critically ill coronavirus patients on ventilators, treated with PLX stem cells from Israel’s Pluristem, survived after 28 days.  Only one of those still needed mechanical ventilation – the other five having been discharged from hospital. 10 … Continue reading →

A patient, with Buerger’s disease was at pre-amputation stage due to non-healing foot ulcers. Regulatory approval was given for compassionate treatment using Pluristem’s PLX-PAD cells. A year after treatment, the wound is fully closed, and the patient has resumed normal … Continue reading →

A new study on stem cells developed by Israeli biotech Pluristem shows they can be used to regulate the immune system, speeding it up or slowing it down as needed. They release a cocktail of therapeutic proteins in response to … Continue reading →

(Thanks to NoCamels) Here again are the details of the stem cell transplants performed by Israeli doctors using PLX stem cells from Israeli biotech Pluristem. Two of the patients were cured completely and one survived for four months until she … Continue reading →

PLX stem cell therapy by Israel’s Pluristem Therapeutics saved a 54-year old Israeli woman with lymphoma cancer and terminal bone marrow failure at Jerusalem’s Hadassah hospital. The patient failed to respond to chemotherapy or bone marrow transplants. She has now … Continue reading →

The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see here) as a treatment for Hematopoietic Acute Radiation Syndrome – a deadly disease that can result from nuclear disasters and radiation … Continue reading →